HGR unknown

back of the envelope valuation., page-5

  1. 3,648 Posts.
    Assuming:

    Max current production is 10,000 units per day.
    Future production to 100,000 units per day?

    Oraline is US$7ea rrp
    Distributor gets 40%
    Retailer gets 30%
    SB gets gets 30% or US$2.10ea
    @production cost is US$0.50ea => SB Profit is $US1.60.
    PE = 10
    #shares = 184m (not counting options!)
    MC (6/12/2007) = A$18M


    CURRENT PRODUCTION/Share Price:

    10,000/day for 240 days/year = 2.4m units produced x US$1.60
    ==> profit = $US3.84m/an

    @PE of 10 => MC = US$38.4m

    sp = US$38.4/0.9(FX) = A$42.7m (for Oraline only)
    ==> sp = A$42.7/184m = 23.2c



    NEW PRODUCTION (given 6 - 12 months to build new prod cap):

    @100,000/day for 240 days/year = 24m produced x US$1.60
    ==> profit = $US38.4m/an

    @PE of 10 => MC = US$384m

    sp = US$384/0.9(FX) = A$426.7m (for Oraline only)
    ==> sp = A$426.7/184m = A$2.31c


    So, even with some conservative numbers, the sp is A$0.23c TODAY and A$2.31c in 6 to 12 months.

    NB: This assumes FDA approval, sales to China, Mexico, Europe and in the US and production is still in the US. However, this kind of production would be more profitable in China, so there is plenty of upside potential too.

    IMO of course.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.